Verici Dx PLC - Tennessee-based developer of clinical diagnostics for organ transplants - Rebrands its post-transplant blood test focused on acute rejection, Tuteva, to Tutivia. Tutivia will be the first test commercialised on the Verici transplant biomarker platform, with a soft commercial launch in the US expected later in 2022.

The other two products on the platform are Clarava, a pre-transplant prognosis test for the risk of early acute rejection, and Protega, a post-transplant test that aims to predict the risk of fibrosis and long-term graft failure.

Current stock price: 13.89 pence, down 10% on Monday

12-month change: down 79%

Copyright 2022 Alliance News Limited. All Rights Reserved.